الفهرس 
Improvement the efficiency of a diuretic drug using nano-particulate systems
ContentsOnly 14 pages are availabe for public view
 |  | from | 121 |  |  |
| | | from | 121 | | |
Abstract
This work aimed at improving the low oral bioavailability of Eplerenone along with evaluating
its ocular effect in treatment of central serous chorioretinopathy (CSCR) using nano-structured
lipid carrier as drug delivery system. A brief review was discussed about pharmacological
aspects of Eplerenone, focusing on CSCR theories, and classification. Different Eplerenone drug
delivery systems were carefully mentioned. Moving on, an inclusive survey of the PubMed
database for articles and case studies up to 2020, relating CSCR patients with EPL were
highlighted. As for Eplerenone nanostructured lipid carrier for oral delivery, they were prepared
using emulsification solvent evaporation technique which proved to give nanometric size
particles, high % entrapped drug and particles of uniform size distribution. Nanostructured lipid
carriers were characterized in terms of particle size (PS), polydispersity index (PDI), zeta
potential (ZP), % entrapment efficiency (% EE), and in-vitro drug release in order to screen for
the optimized formulations. The selected formulation was evaluated for possible ingredients
interactions using Fourier transform infrared spectroscopy (FT-IR), powder X-ray diffraction,
and their morphology using Transmission electron microscopy (TEM). Ex-vivo study on rabbit
intestine was conducted to evaluate the permeation behavior. The selected formulation proved
superior to pure aqueous Eplerenone suspension. As for Eplerenone modified nanostructured
lipid carrier for ocular delivery in CSCR treatment, they were fabricated by emulsification
solvent evaporation technique followed by simple modification (coating) with coating polymers
under magnetic stirring. Modified carriers were characterized in (PS), polydispersity index
(PDI), zeta potential (ZP), % entrapment efficiency (% EE), and viscosity measurement. The
selected nano-systems were further evaluated for their in-vitro release, in-vitro irritation using
hen’s egg test on chorioallantoic membrane, mucoadhesion, pH, refractive index, and TEM.
Future in-vivo studies was conducted with the purpose of considering the in-vivo corneal
irritation on laboratory animals through Draize test and histopathological examination, and for
screening the transcorneal permeation by confocal laser microscopy. The final conclusions
represent a direct approach for Eplerenone ocular delivery and replace the necessity of oral use